Chronic Lymphocytic Leukaemia - KOL Insight

How do the experts see the potential for fixed-duration combination treatments playing out in first-line CLL therapy? Why do KOLs say AstraZeneca's Calquence + AbbVie/Roche's Venclexta combination is important? What opportunities lie ahead for BeiGene's Brukinsa? How do KOLs assess the potential of BTK degraders such as Nurix's NX-5948 and BeiGene's BGB-16673? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (11)

Current and future treatment algorithm

Research objectives (2)

Bruton's tyrosine kinase (BTK) inhibitors/degraders (66)

• Approved BTK inhibitors (46)
  • Imbruvica (ibrutinib; AbbVie/J&J) (11)
  • Calquence (acalabrutinib; AstraZeneca) (11)
  • Brukinsa (zanubrutinib; BeiGene) (9)
  • Jaypirca (pirtobrutinib; Lilly) (15)
• Pipeline BTK inhibitors and degraders (20)
  • Nemtabrutinib (Merck & Co.) (10)
  • NX-5948, NX-2127 (Nurix Therapeutics) & BGB-16673 (BeiGene) (10)

Bcl-2 inhibitors (19)

• Approved therapies (10)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (10)
• Pipeline therapies (9)
  • Sonrotoclax (BGB-11417; BeiGene) and lisaftoclax (Ascentage Pharma) (9)

CAR T-cell therapies (16)

• Pipeline drugs (16)
  • Breyanzi (lisocabtagene maraleucel; Bristol Myers Squibb) (11)
  • MB-106 (Mustang Bio) (5)

Bispecific antibodies (8)

• Pipeline drugs (8)
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab) and Columvi (glofitamab; Roche) (8)

Future treatment trends (5)

• Key insights summary (5)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)